Both BMS and Novo Nordisk have, in recent months, announced steep layoffs as they strive to cut back on costs.

The star of the acquisition, which includes a contingent value right of $6 per share, is pegozafermin, an FGF21 analog in ...

DB1, a capsid developed by Shape Therapeutics, to deliver therapies to the brain, including VectorY’s developmental ...

Supporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage ...

In this episode of Denatured, BioSpace’s head of insights Lori Ellis and Colin Zick, partner at Foley Hoag LLP, spend time ...

An IQVIA report published earlier this year found that 43% of anti-obesity assets currently in development are orally administered. By 2030, Goldman Sachs predicts this will translate to the pills’ ...

A complex state vs. federal regulatory scheme allows drug compounders to advertise drugs without disclosing risks like a ...

OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster ...

Moving forward, Innate will focus on the clinical development of its antibody-drug conjugate IPH4502, the lymphoma candidate ...

Transparency doesn’t drive people away. It attracts the right ones and keeps them committed. Leadership coach Angela Justice ...

In letters to Eli Lilly and Novo Nordisk, the FDA accused the companies of downplaying the risks of their GLP-1 weight loss ...

This manufacturing site in Richmond, Virginia, is the first of four projects that Eli Lilly plans to reveal this year as part ...